Loading…
Loading…
OASMY (Vivesto AB) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for OASMY and 80,000+ other tickers.
See exactly how OASMY's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for OASMY and 80,000+ other tickers.
Vivesto AB develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma. The company also offers Apealea, an injectable formulation of paclitaxel for the treatment of various cancers. In addition, it develops Cantrixil, a drug candidate for the treatment of advanced cancer, and Docetaxel micellar for the treatment of prostate cancer. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its…
Acrivon Therapeutics (NASDAQ: ACRV - Get Free Report) and Oasmia Pharmaceutical (OTCMKTS:OASMY - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations, institutional ownership and dividends. Valuation and Earnings This table compares Acrivon
Vivesto AB (OTC:OASMY) Discusses Pipeline Advancements in Paccal Vet and Cantrixil and Strategic Capital Raise November 24, 2025 9:00 AM EST Company Participants Peter Zonabend Erik Kinnmann - Chief Executive Officer Henrik Rönnberg - Chief Medical Officer of Animal Health Teresa Zafra - Chief Scientific Officer & Head of Preclinical Development & Clinical Operations Johanna Rostin - Chief Regulatory Officer Conference Call Participants Mikael Magnusson James Perry Bjørn Tore Gjertsen Nina Herne Presentation Mikael Magnusson The clock strikes 3:00 p.m., and we welcome viewers here to Vivesto's business update.